EP4149552A4 - Zusammensetzungen und verfahren zur erhöhung der wirksamkeit eines arzneimittels - Google Patents

Zusammensetzungen und verfahren zur erhöhung der wirksamkeit eines arzneimittels Download PDF

Info

Publication number
EP4149552A4
EP4149552A4 EP21803283.7A EP21803283A EP4149552A4 EP 4149552 A4 EP4149552 A4 EP 4149552A4 EP 21803283 A EP21803283 A EP 21803283A EP 4149552 A4 EP4149552 A4 EP 4149552A4
Authority
EP
European Patent Office
Prior art keywords
effectiveness
drug
compositions
increasing
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21803283.7A
Other languages
English (en)
French (fr)
Other versions
EP4149552A1 (de
Inventor
Sina Bavari
Simon NEWMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Ltd Ireland
Original Assignee
Healion Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healion Bio Inc filed Critical Healion Bio Inc
Publication of EP4149552A1 publication Critical patent/EP4149552A1/de
Publication of EP4149552A4 publication Critical patent/EP4149552A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21803283.7A 2020-05-15 2021-05-14 Zusammensetzungen und verfahren zur erhöhung der wirksamkeit eines arzneimittels Withdrawn EP4149552A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025770P 2020-05-15 2020-05-15
PCT/US2021/032461 WO2021231872A1 (en) 2020-05-15 2021-05-14 Compositions and methods for increasing efficacy of a drug

Publications (2)

Publication Number Publication Date
EP4149552A1 EP4149552A1 (de) 2023-03-22
EP4149552A4 true EP4149552A4 (de) 2024-06-19

Family

ID=78525057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21803283.7A Withdrawn EP4149552A4 (de) 2020-05-15 2021-05-14 Zusammensetzungen und verfahren zur erhöhung der wirksamkeit eines arzneimittels

Country Status (5)

Country Link
EP (1) EP4149552A4 (de)
JP (1) JP2023526327A (de)
CN (1) CN116157152A (de)
AU (1) AU2021271806A1 (de)
WO (1) WO2021231872A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857617B2 (en) * 2021-05-10 2024-01-02 Topelia Aust Limited (652 771 670) Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
CN114957381B (zh) * 2021-10-22 2026-04-17 广州谷森制药有限公司 新型氘代氰基类化合物、其制备方法、组合物及应用
EP4452220A1 (de) * 2021-12-23 2024-10-30 Subintro Limited Neue antivirale zusammensetzungen mit ölsäure
CN114409727A (zh) * 2021-12-28 2022-04-29 苏州康纯医药科技有限公司 一种抗冠状病毒的3clpro抑制剂的制备方法
WO2023132842A1 (en) * 2022-01-10 2023-07-13 AiPharma Global Holdings LLC Drug combination to treat microbial infections including coronavirus
CN120112285A (zh) * 2022-11-03 2025-06-06 上海科技大学 Aloxistatin在制备抗病毒感染的药物中的应用
CN116421608B (zh) * 2023-03-29 2025-08-08 中国疾病预防控制中心病毒病预防控制所 加利地韦在体外抑制狂犬病病毒中的应用
CN118090994B (zh) * 2024-04-26 2024-06-21 上海安谱实验科技股份有限公司 一种包含利托那韦和基质的稳定冻干剂、制备方法、试剂盒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021191875A1 (en) * 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
WO2021231570A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of Michigan Cysteamine for the treatment of sars-cov-2 infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004933A (en) * 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
CA2850003C (en) * 2011-09-27 2020-01-07 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
WO2019032726A1 (en) * 2017-08-09 2019-02-14 Cutanea Life Sciences, Inc. METHODS OF TREATMENT AND PREVENTION OF VIRAL INFECTIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021191875A1 (en) * 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
WO2021231570A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of Michigan Cysteamine for the treatment of sars-cov-2 infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MANLI WANG ET AL: "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", CELL RESEARCH, 4 February 2020 (2020-02-04), Singapore, XP055672526, ISSN: 1001-0602, DOI: 10.1038/s41422-020-0282-0 *
NAIONAL INSTITUTES OF HEALTH: "Therapeutic Options Under Investigation | Coronavirus Disease COVID-19", 21 April 2020 (2020-04-21), pages 1, XP093153428, Retrieved from the Internet <URL:https://web.archive.org/web/20200421163941/https://covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/> *
See also references of WO2021231872A1 *

Also Published As

Publication number Publication date
EP4149552A1 (de) 2023-03-22
JP2023526327A (ja) 2023-06-21
WO2021231872A1 (en) 2021-11-18
AU2021271806A1 (en) 2022-12-15
CN116157152A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
EP4149552A4 (de) Zusammensetzungen und verfahren zur erhöhung der wirksamkeit eines arzneimittels
EP4034253A4 (de) Zusammensetzungen und verfahren zur erhöhung der wirksamkeit von immuntherapien und impfstoffen
EP3924481A4 (de) Zusammensetzungen und verfahren zur behandlung von hämoglobinopathien
EP3781705A4 (de) Zusammensetzungen und verfahren zur geneditierung
EP4277616A4 (de) Transdermale penetrationsformulierungen zur verabreichung von medikamenten
MA52861A (fr) Méthodes et compositions pour le traitement de l&#39;apnée du sommeil
EP3768242A4 (de) Verfahren und zusammensetzungen zur gezielten abgabe von wirkstoffen und immunmodulatorischen mitteln an lymphknoten
EP3921420A4 (de) Arzneimittelabgabezusammensetzungen zur okularen verabreichung von therapeutika und verwendungsverfahren dafür
EP3743091A4 (de) Verfahren und zusammensetzungen zur behandlung angiogener störungen unter verwendung von anti-vegf-mitteln
EP4121022A4 (de) Zusammensetzungen und verfahren zur behandlung und prävention einer coronavirusinfektion
EP4297784A4 (de) Zusammensetzungen und verfahren zur therapeutischen verabreichung
EP4337203A4 (de) Inhibitoren der menin-mll-interaktion
EP3920898A4 (de) Verfahren und zusammensetzungen zur behandlung von schlafapnoe
EP4058062A4 (de) Zusammensetzungen und verfahren für die immuntherapie
EP3810091A4 (de) Verfahren und zusammensetzungen zur behandlung pulmonaler hypertonie
MA52587A (fr) Composés d&#39;azabenzimidazole et produit pharmaceutique
EP4114422A4 (de) Zusammensetzungen und verfahren zur behandlung intrazellulärer bakterieller infektionen
EP3951290A4 (de) Kühlschrank und brühvorrichtung für kühlschrank
EP3768301A4 (de) Zusammensetzungen und verfahren zur fas-hemmung
EP4073060A4 (de) Lysinspezifische histon-demethylase-inhibitoren zur behandlung von myeloproliferativen neoplasmen
EP3876955A4 (de) Verfahren und zusammensetzungen zur bestimmung der zusammensetzung einer tumormikroumgebung
EP3946380A4 (de) Zusammensetzungen und verfahren für die krebsimmuntherapie
MA53333A (fr) Formulations pharmaceutiques d&#39;anticorps masqués
EP3740247A4 (de) Zusammensetzungen und verfahren zur hemmung der gys2-expression
MA51869A (fr) Compositions et méthodes pour l&#39;édition génique par ciblage du fibrinogène-alpha

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091220

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0041000000

Ipc: A61K0031495000

A4 Supplementary search report drawn up and despatched

Effective date: 20240522

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20240515BHEP

Ipc: A61P 31/12 20060101ALI20240515BHEP

Ipc: A61K 45/06 20060101ALI20240515BHEP

Ipc: A61K 31/4965 20060101ALI20240515BHEP

Ipc: A61K 31/495 20060101AFI20240515BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TONIX PHARMA LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241212